Polyganics Awarded €1.2 Million to Complete Clinical Development of Dura Sealant Patch
Summary
First-in-human clinical studies of the device expected to begin in early 2018 Groningen, The Netherlands, December 01, 2017 / B3C newswire / -- Polyganics, a privately held medical technology company that develops, manufactures and commercializes bioresorbable medical devices, today announced it has been awarded funding from the European Fund for Regional Development (ERDF) by the European Union, to support clinical validation of its dura sealant patch. Rudy Mareel, CEO of Polyganics, commented: “We are hugely appreciative to the EU, as well as the city and province of Groningen for their support in progressing the device into the next phase of its development. If the quality of dural closure is improved, complications associated with CSF leakage, including meningitis, pseudomeningoceles, impaired wound healing, and subgaleal fluid collection, could be reduced. In 2014, Polyganics sold its Ear, Nose & Throat (ENT) surgery business unit (the NASOPORE® product family including HEMOPORE®, SINUPORE® and OTOPORE®) to Stryker, one of the world’s leading medical technology companies. Polyganics Paul Roos, Chief Financial Officer Romke Ribbels, Director Marketing & Business Development +31 50 588 65 88 This email address is being protected from spambots.